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Proper maintenance of chromosomes requires dealing with
two biological challenges: the chromosome end-protection
problem and the chromosome end-replication problem [1].
The first challenge stems from the need to distinguish the
ends of linear chromosomes, which predominate in
eukaryotes, from broken DNA ends that require repair.
The second challenge stems from the gradual loss of
sequence information at the extreme end of chromosomes,
owing to incomplete replication by DNA polymerases
(which only synthesize DNA in the 50 to 30 direction and
are unable to fill in the gap left behind upon removal of the
50-most RNA primer). Telomerase, a unique enzyme that
contains telomerase reverse transcriptase (TERT) and a
template-containing RNA component (telomerase RNA
[TR]), extends telomeric DNA to solve both problems.
In mammals, the action of telomerase is required for the
survival of continuously dividing cells such as embryonic
cells and adult stem cells. These cells have relatively high
levels of telomerase activity, whereas most somatic cells,
which have a limited replicative lifespan, have very low or
undetectable telomerase activity. Inactivation of telome-
rase in these latter cells is achieved mostly by transcrip-
tional downregulation of the TERT gene, which encodes
the essential, catalytically active protein subunit of the
enzyme [2]. TERT protein associates with the essential
TR subunit of the enzyme, which templates telomere
extension, and with other protein factors to form the active
holoenzyme that maintains telomere length [1].
TERT expression is also sometimes regulated by produc-
tion of alternatively splicedmessenger RNA (mRNA) variants
that delete essential reverse transcriptase motifs of the
enzyme. Increased abundance of these variants correlates
with inactivation of telomerase during tissue differentiation,
whereas increased levels of mRNAs encoding full-length
TERT occur in some lymphomas and activated T cells [3–6].
Most cancer cells (85–90%) upregulate TERT protein to
reactivate telomerase and maintain telomere lengths
through an indefinite number of cell divisions, and the
remainder also maintain telomere length through an
alternative lengthening of telomeres mechanism.
Recently, TERT promoter mutations have been found at
high frequency in many diverse cancers but not in adjacent
normal tissue [7,8]. An exciting breakthrough was finding
point mutations in the TERT gene promoter in 66% of
urothelial carcinomas of the bladder [7,8]. These mutations
were first reported inmelanoma [9,10] and quickly found in
other cancers [7,8,10]. In contrast, only 1% of cancers have
mutations in the TERT open reading frame [11], and even
these have not been shown to be activating mutations,
suggesting that telomerase reactivation is primarily
achieved through increased gene expression by transacting
factors. Although these promoter mutations were hypothe-
sized to increase expression of TERT by generating
additional binding sites for E-twenty-six (ETS) transcription
factors, only 1.15- to 2-fold increases in expression were
found using a luciferase reporter gene system [9,10,12].
Additional mechanistic analysis is needed to determine if
such modest increases in TERT expression can indeed drive
immortalization or if the artificial reporter gene systems
greatly underestimate the effect of the mutation; certainly
other possibilities exist as well.
In this month’s issue of European Urology, two studies
[13,14] follow up on these investigations and show that
mutation analysis of the TERT promoter allows bladder
tumor cells to be detected in urine. In addition, these studies
show that TERT promoter mutations are found at similar
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frequency across tumor stage, and there is lack of
association with clinical outcome. These exciting studies
further reinvigorate recent interest in telomerase in
urothelial carcinoma that began in the early 1990s. In
1995, work indicated that in human urothelial carcinoma,
telomere length was reduced in tumor tissue, more so in
non–muscle-invasive than in invasive tumors, whereas
telomerase was detectable only in tumor tissues and its
activity was surprisingly unrelated to telomere length [15].
Other early work reported that telomerase activity had an
association with the pathologic grade and clinical stage,
with most advanced grade and deeply invasive tumors
having high telomerase activity [16]. Many subsequent
studies addressed whether telomerase could be used in
some manner to detect bladder cancer [17], but none
progressed to the clinical realm.
Taken together, these recent findings answer some
questions and raise many others. It now appears that using
current molecular technology, we can potentially detect
approximately two-thirds of bladder cancers by searching
for TERT promoter mutations in the urine. The clinical
specificity, sensitivity, and positive and negative predictive
values determined in larger prospective studies will be key
in determining the value of any clinical test based on this
observation. An important message also delivered by these
studies is that TERT promoter mutations are not preferen-
tially associated with either non–muscle-invasive or inva-
sive bladder cancer and thus are likely to be a requirement
for transformation or maintenance of malignancy in most
urothelial tumors. Somewhat paradoxically, bladder can-
cers have shorter telomeres than cognate normal urothe-
lium [15], also raising a question about the impact of these
mutations. We do not yet understand the true biological
contribution of these mutations to the malignant pheno-
type in urothelial carcinoma biology. Nevertheless, further
work on this gene, its regulation, and its clinical utility will
be very exciting, as it will likely lead to novel and practical
insights into bladder cancer biology. In addition, we expect
that these findings will rekindle interest in telomerase as an
attractive therapeutic target.
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